Lux Med Onkologia Sp. z o.o.
- Address
- Ul. Gen. Augusta Emila Fieldorfa Nila 40, 04-125 Warsaw, Poland
Lux Med Onkologia Sp. z o.o.
Lux Med Onkologia Sp. z o.o. is a specialized oncology research center dedicated to advancing cancer treatment through participation in innovative clinical trials. The center demonstrates particular expertise in breast cancer research, focusing on novel therapeutic approaches for patients with advanced disease.
- Hormone receptor-positive (HR+) and HER2-negative breast cancer
- Immunotherapy combinations with chemotherapy in metastatic settings
- Locally recurrent inoperable and metastatic breast cancer treatment
The center actively participates in pivotal international trials investigating pembrolizumab-based immunotherapy regimens combined with chemotherapy for patients with advanced breast cancer. Their research focuses on evaluating novel treatment strategies for patients with PD-L1 positive tumors who have not previously received cytotoxic chemotherapy in the noncurative setting, contributing to the development of personalized oncology approaches that may improve progression-free survival and clinical outcomes for breast cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lux Med Onkologia Sp. z o.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion | Bristol-Myers Squibb Services Unlimited Company | Phase IV | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2021-08-05 | 2025-11-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.